Mona Bratter had trouble breathing after surgery in 2023 to treat her small-cell lung cancer (SCLC). But when her oncologist suggested palliative care to help manage her discomfort, she was hesitant. ...
CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial ...
Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors by ...
ES-SCLC patients show limited benefit from 3L therapies, highlighting the need for novel treatments to improve outcomes. SCLC is aggressive, often diagnosed at an extensive stage, and treated with ...
The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...
Hosted on MSN
Immunotherapy For Small Cell Lung Cancer: Groundbreaking New Developments Offer Hope To Patients
For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope. Exciting new research presented at the American Society of Clinical Oncology (ASCO) 2025 conference is ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...
In a multicentre study, lurbinectedin demonstrated a favourable safety profile and consistent efficacy and may be considered for compassionate use in patients with extensive-stage small cell lung ...
The IMforte trial showed Zepzelca plus Tecentriq improved progression-free and overall survival in extensive-stage SCLC, suggesting a new first-line maintenance standard. DELPHI-304 demonstrated ...
The global downturn in tobacco use has led to a significant decline in the number of patients who are diagnosed with small-cell lung cancer (SCLC) on a yearly basis. But for those who do have SCLC, ...
Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...
A phase 3 randomized study found no OS benefit from adding 30 Gy/10 fractions thoracic radiotherapy starting after cycle 1 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results